<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36741410</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: A Mendelian randomization.</ArticleTitle><Pagination><StartPage>985729</StartPage><MedlinePgn>985729</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">985729</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.985729</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Previous studies have reported that a few inflammatory cytokines have associations with systemic lupus erythematosus (SLE)-for example, IL-6, IL-17, and macrophage inflammatory protein (MIP). This Mendelian randomization was conducted to further assess the causal correlations between 41 inflammatory cytokines and SLE.</AbstractText><AbstractText Label="METHODS">The two-sample Mendelian randomization utilized genetic variances of SLE from a large publicly available genome-wide association study (GWAS) (7,219 cases and 15,991 controls of European ancestry) and inflammatory cytokines from a GWAS summary containing 8,293 healthy participants. Causalities of exposures and outcomes were explored mainly using inverse variance weighted method. In addition, multiple sensitivity analyses including MR-Egger, weighted median, simple mode, weighted mode, and MR-PRESSO were simultaneously applied to strengthen the final results.</AbstractText><AbstractText Label="RESULTS">The results indicated that cutaneous T cell-attracting chemokine (CTACK) and IL-17 may be suggestively associated with the risk of SLE (odds ratio, OR: 1.21, 95%CI: 1.04-1.41, <i>p</i> = 0.015; OR: 1.37, 95%CI: 1.03-1.82, <i>p</i> = 0.029). In addition, cytokines including beta nerve growth factor, basic fibroblast growth factor, IL-4, IL-6, interferon gamma-induced protein 10, monokine induced by interferon-gamma, MIP1b, stromal cell-derived factor-1 alpha, and tumor necrosis factor-alpha are suggested to be the consequences of SLE disease (Beta: 0.035, <i>p</i> = 0.014; Beta: 0.021, <i>p</i> = 0.032; Beta: 0.024, <i>p</i> = 0.013; Beta: 0.019, <i>p</i> = 0.042; Beta: 0.040, <i>p</i> = 0.005; Beta: 0.046, <i>p</i> = 0.001; Beta: 0.021, <i>p</i> = 0.029; Beta: 0.019, <i>p</i> = 0.045; Beta: 0.029, <i>p</i> = 0.048).</AbstractText><AbstractText Label="CONCLUSION">This study suggested that CTACK and IL-17 are probably the factors correlated with SLE etiology, while a couple of inflammatory cytokines are more likely to be involved in SLE development downstream.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Xiang, Wang, Gao, Wang, Chen, Sun, Liang and Xu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Mengmeng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yilun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhanyan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GWAS</Keyword><Keyword MajorTopicYN="N">Mendelian randomization</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>3</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36741410</ArticleId><ArticleId IdType="pmc">PMC9893779</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.985729</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov (2014) 13:173&#x2013;4. doi:&#xa0;10.1038/nrd4227</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4227</ArticleId><ArticleId IdType="pubmed">24525782</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigante D, Esposito S. Infections and systemic lupus erythematosus: Binding or sparring partners? Int J Mol Sci (2015) 16:17331&#x2013;43. doi:&#xa0;10.3390/ijms160817331</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160817331</ArticleId><ArticleId IdType="pmc">PMC4581196</ArticleId><ArticleId IdType="pubmed">26230690</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein A, Alexander RV, Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep (2021) 23:16. doi:&#xa0;10.1007/s11926-021-00984-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00984-1</ArticleId><ArticleId IdType="pmc">PMC7875837</ArticleId><ArticleId IdType="pubmed">33569681</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine (2015) 72:146&#x2013;53. doi:&#xa0;10.1016/j.cyto.2014.12.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2014.12.027</ArticleId><ArticleId IdType="pubmed">25647269</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. J Autoimmun (2021) 119:102615. doi:&#xa0;10.1016/j.jaut.2021.102615</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102615</ArticleId><ArticleId IdType="pmc">PMC8044029</ArticleId><ArticleId IdType="pubmed">33631651</ArticleId></ArticleIdList></Reference><Reference><Citation>Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare: Altered inflammatory mediators preceding SLE flare. Arthritis Rheumatol (2014) 66:1888&#x2013;99. doi:&#xa0;10.1002/art.38573</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38573</ArticleId><ArticleId IdType="pmc">PMC4128244</ArticleId><ArticleId IdType="pubmed">24578190</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol (2013) 37:658&#x2013;65. doi:&#xa0;10.1002/gepi.21758</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21758</ArticleId><ArticleId IdType="pmc">PMC4377079</ArticleId><ArticleId IdType="pubmed">24114802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al. . Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a mendelian randomisation study. Psychol Med (2020) 50:2435&#x2013;43. doi:&#xa0;10.1017/S0033291719002678</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291719002678</ArticleId><ArticleId IdType="pmc">PMC7610182</ArticleId><ArticleId IdType="pubmed">31689377</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, EPIC- InterAct Consortium . Using published data in mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol (2015) 30:543&#x2013;52. doi:&#xa0;10.1007/s10654-015-0011-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0011-z</ArticleId><ArticleId IdType="pmc">PMC4516908</ArticleId><ArticleId IdType="pubmed">25773750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol (2016) 45:1717&#x2013;26. doi:&#xa0;10.1093/ije/dyx028</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyx028</ArticleId><ArticleId IdType="pmc">PMC5722032</ArticleId><ArticleId IdType="pubmed">28338968</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. . Strengthening the reporting of observational studies in epidemiology using mendelian randomization: The STROBE-MR statement. JAMA (2021) 326:1614. doi:&#xa0;10.1001/jama.2021.18236</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.18236</ArticleId><ArticleId IdType="pubmed">34698778</ArticleId></ArticleIdList></Reference><Reference><Citation>Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA (2017) 318:1925&#x2013;6. doi:&#xa0;10.1001/jama.2017.17219</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.17219</ArticleId><ArticleId IdType="pubmed">29164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce BL, Ahsan H, VanderWeele TJ. Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol (2011) 40:740&#x2013;52. doi:&#xa0;10.1093/ije/dyq151</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyq151</ArticleId><ArticleId IdType="pmc">PMC3147064</ArticleId><ArticleId IdType="pubmed">20813862</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. . Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res (2012) 21:223&#x2013;42. doi:&#xa0;10.1177/0962280210394459</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280210394459</ArticleId><ArticleId IdType="pmc">PMC3917707</ArticleId><ArticleId IdType="pubmed">21216802</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics (2015) 31:3555&#x2013;7. doi:&#xa0;10.1093/bioinformatics/btv402</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv402</ArticleId><ArticleId IdType="pmc">PMC4626747</ArticleId><ArticleId IdType="pubmed">26139635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J, Morris DL, Cunninghame Graham DS, Pinder CL, Tombleson P, Behrens TW, et al. . Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet (2015) 47:1457&#x2013;64. doi:&#xa0;10.1038/ng.3434</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3434</ArticleId><ArticleId IdType="pmc">PMC4668589</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahola-Olli AV, W&#xfc;rtz P, Havulinna AS, Aalto K, Pitk&#xe4;nen N, Lehtim&#xe4;ki T, et al. . Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am J Hum Genet (2017) 100:40&#x2013;50. doi:&#xa0;10.1016/j.ajhg.2016.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.11.007</ArticleId><ArticleId IdType="pmc">PMC5223028</ArticleId><ArticleId IdType="pubmed">27989323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol (2016) 40:304&#x2013;14. doi:&#xa0;10.1002/gepi.21965</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21965</ArticleId><ArticleId IdType="pmc">PMC4849733</ArticleId><ArticleId IdType="pubmed">27061298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol (2015) 44:512&#x2013;25. doi:&#xa0;10.1093/ije/dyv080</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv080</ArticleId><ArticleId IdType="pmc">PMC4469799</ArticleId><ArticleId IdType="pubmed">26050253</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet (2018) 50:693&#x2013;8. doi:&#xa0;10.1038/s41588-018-0099-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0099-7</ArticleId><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Lee S, Won S. Causal evaluation of laboratory markers in type 2 diabetes on cancer and vascular diseases using various mendelian randomization tools. Front Genet (2020) 11:597420. doi:&#xa0;10.3389/fgene.2020.597420</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.597420</ArticleId><ArticleId IdType="pmc">PMC7780896</ArticleId><ArticleId IdType="pubmed">33408737</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis MK, Gill D, Rannikm&#xe4;e K, Traylor M, Anderson CD, MEGASTROKE consortium of the International Stroke Genetics Consortium (ISGC) et al. . Genetically determined levels of circulating cytokines and risk of stroke: Role of monocyte chemoattractant protein-1. Circulation (2019) 139:256&#x2013;68. doi:&#xa0;10.1161/CIRCULATIONAHA.118.035905</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035905</ArticleId><ArticleId IdType="pmc">PMC7477819</ArticleId><ArticleId IdType="pubmed">30586705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. . The MR-base platform supports systematic causal inference across the human phenome. eLife (2018) 7:e34408. doi:&#xa0;10.7554/eLife.34408</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.34408</ArticleId><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan H, Li H, Liu C, Cheng L, Yan S, Li Y. Association of circulating vascular endothelial growth factor levels with autoimmune diseases: A systematic review and meta-analysis. Front Immunol (2021) 12:674343. doi:&#xa0;10.3389/fimmu.2021.674343</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.674343</ArticleId><ArticleId IdType="pmc">PMC8191579</ArticleId><ArticleId IdType="pubmed">34122433</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M, Feng Y, Wang Y, Wang J, Zhang Z, Liang J, et al. . Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis. Sci Rep (2021) 11:4707. doi:&#xa0;10.1038/s41598-021-84170-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84170-4</ArticleId><ArticleId IdType="pmc">PMC7907126</ArticleId><ArticleId IdType="pubmed">33633218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H-H, Fan Y, Wang Y-N, Zhao C-N, Zhang Z-K, Pan H-F, et al. . Elevated circulating interleukin-17 levels in patients with systemic lupus erythematosus: A meta-analysis. Immunol Invest (2020) 49:662&#x2013;75. doi:&#xa0;10.1080/08820139.2019.1699107</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2019.1699107</ArticleId><ArticleId IdType="pubmed">31847623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamada MM, Jia Y, Wu X. Macrophage polarization and plasticity in systemic lupus erythematosus. Front Immunol (2021) 12:734008. doi:&#xa0;10.3389/fimmu.2021.734008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.734008</ArticleId><ArticleId IdType="pmc">PMC8721097</ArticleId><ArticleId IdType="pubmed">34987500</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet (2014) 23:R89&#x2013;98. doi:&#xa0;10.1093/hmg/ddu328</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu328</ArticleId><ArticleId IdType="pmc">PMC4170722</ArticleId><ArticleId IdType="pubmed">25064373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekula P, Del Greco MF, Pattaro C, K&#xf6;ttgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol (2016) 27:3253&#x2013;65. doi:&#xa0;10.1681/ASN.2016010098</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016010098</ArticleId><ArticleId IdType="pmc">PMC5084898</ArticleId><ArticleId IdType="pubmed">27486138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity (2002) 16:1&#x2013;4. doi:&#xa0;10.1016/S1074-7613(01)00261-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(01)00261-8</ArticleId><ArticleId IdType="pubmed">11825560</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakawa M, Kishimoto M, Ohtsuki M, Komine M. Calcipotriol induces the production of CTACK/CCL27, one of the potential suppressive factors in psoriasis inflammation. J Dermatol (2021) 48:1949&#x2013;50. doi:&#xa0;10.1111/1346-8138.16152</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.16152</ArticleId><ArticleId IdType="pubmed">34505709</ArticleId></ArticleIdList></Reference><Reference><Citation>Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. . Biomarkers in atopic dermatitis&#x2013;a review on behalf of the international eczema council. J&#xa0;Allergy Clin Immunol (2021) 147:1174&#x2013;1190.e1. doi:&#xa0;10.1016/j.jaci.2021.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.01.013</ArticleId><ArticleId IdType="pubmed">33516871</ArticleId></ArticleIdList></Reference><Reference><Citation>Machura E, Rusek-Zychma M, Jachimowicz M, Wrzask M, Mazur B, Kasperska-Zajac A. Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria: TARC, CTACK in allergy in children. Pediatr Allergy Immunol (2012) 23:278&#x2013;84. doi:&#xa0;10.1111/j.1399-3038.2011.01225.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3038.2011.01225.x</ArticleId><ArticleId IdType="pubmed">22017510</ArticleId></ArticleIdList></Reference><Reference><Citation>Song TW, Sohn MH, Kim ES, Kim KW, Kim K-E. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. Clin Exp Allergy (2006) 36:346&#x2013;51. doi:&#xa0;10.1111/j.1365-2222.2006.02430.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2222.2006.02430.x</ArticleId><ArticleId IdType="pubmed">16499646</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Stramazzotti D, et al. . CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol (2007) 157:1155&#x2013;60. doi:&#xa0;10.1111/j.1365-2133.2007.08200.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2007.08200.x</ArticleId><ArticleId IdType="pubmed">17916208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, et al. . Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol (2003) 111:592&#x2013;7. doi:&#xa0;10.1067/mai.2003.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mai.2003.114</ArticleId><ArticleId IdType="pubmed">12642842</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity (2019) 50:892&#x2013;906. doi:&#xa0;10.1016/j.immuni.2019.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.021</ArticleId><ArticleId IdType="pmc">PMC6474359</ArticleId><ArticleId IdType="pubmed">30995505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 28:454&#x2013;67. doi:&#xa0;10.1016/j.immuni.2008.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.03.004</ArticleId><ArticleId IdType="pmc">PMC3424508</ArticleId><ArticleId IdType="pubmed">18400188</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga T, Ichinose K, Kawakami A, Tsokos GC. Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus. Front Immunol (2021) 11:624971. doi:&#xa0;10.3389/fimmu.2020.624971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.624971</ArticleId><ArticleId IdType="pmc">PMC7882681</ArticleId><ArticleId IdType="pubmed">33597953</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther (2014) 16:R23. doi:&#xa0;10.1186/ar4451</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4451</ArticleId><ArticleId IdType="pmc">PMC3978465</ArticleId><ArticleId IdType="pubmed">24460726</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Fu T, Ji J, Li Z, Gu Z. The role of interleukin-4 in rheumatic diseases. Clin Exp Pharmacol Physiol (2018) 45:747&#x2013;54. doi:&#xa0;10.1111/1440-1681.12946</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1440-1681.12946</ArticleId><ArticleId IdType="pubmed">29655253</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley S, Mok CC, Vanarsa K, Habazi D, Li J, Pedroza C, et al. . Identification of low-abundance urinary biomarkers in lupus nephritis using electrochemiluminescence immunoassays. Arthritis Rheumatol (2019) 71:744&#x2013;55. doi:&#xa0;10.1002/art.40813</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40813</ArticleId><ArticleId IdType="pubmed">30618193</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan W, An J, Li G, Qian G, Jin M, Feng C, et al. . Th Cytokine profile in childhood-onset systemic lupus erythematosus. BMC Pediatr (2021) 21:187. doi:&#xa0;10.1186/s12887-021-02659-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-021-02659-3</ArticleId><ArticleId IdType="pmc">PMC8059275</ArticleId><ArticleId IdType="pubmed">33882880</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H, Eketj&#xe4;ll S, Pettersson S, Gustafsson JT, Zickert A, Kvarnstr&#xf6;m M, et al. . TNF-&#x3b1; and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Sci Med (2018) 5:e000260. doi:&#xa0;10.1136/lupus-2018-000260</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000260</ArticleId><ArticleId IdType="pmc">PMC6018889</ArticleId><ArticleId IdType="pubmed">29955370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EY, Lee Z-H, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev (2009) 8:379&#x2013;83. doi:&#xa0;10.1016/j.autrev.2008.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.12.002</ArticleId><ArticleId IdType="pubmed">19105984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lit LCW, Wong CK, Tam LS, Li EKM, Lam CWK. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis (2006) 65:209&#x2013;15. doi:&#xa0;10.1136/ard.2005.038315</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.038315</ArticleId><ArticleId IdType="pmc">PMC1798029</ArticleId><ArticleId IdType="pubmed">15975968</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gohary A, Hegazy A, Abbas M, Kamel N, Nasef SI. Serum and urinary interferon-Gamma-Inducible protein 10 in lupus nephritis. J Clin Lab Anal (2016) 30:1135&#x2013;8. doi:&#xa0;10.1002/jcla.21993</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.21993</ArticleId><ArticleId IdType="pmc">PMC6806674</ArticleId><ArticleId IdType="pubmed">27184880</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 6:339&#x2013;47. doi:&#xa0;10.1038/nrrheum.2010.64</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.64</ArticleId><ArticleId IdType="pubmed">20440285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, et al. . Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis (2017) 76:534&#x2013;42. doi:&#xa0;10.1136/annrheumdis-2016-209668</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209668</ArticleId><ArticleId IdType="pmc">PMC5446001</ArticleId><ArticleId IdType="pubmed">27672124</ArticleId></ArticleIdList></Reference><Reference><Citation>Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. . Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 62:542&#x2013;52. doi:&#xa0;10.1002/art.27221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27221</ArticleId><ArticleId IdType="pmc">PMC3057537</ArticleId><ArticleId IdType="pubmed">20112381</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: Value for diagnosis and drug therapy. Int J Mol Sci (2021) 22:11327. doi:&#xa0;10.3390/ijms222111327</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111327</ArticleId><ArticleId IdType="pmc">PMC8582965</ArticleId><ArticleId IdType="pubmed">34768756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>